Trump's 200% Tariff Threat on Generic Drugs Hits Indian Pharma Stocks
UPSC / SSC current affairs note · Economy
Why in news
US President Donald Trump announced a phased tariff imposition on generic drugs, causing Indian pharma stocks to plummet. The Nifty Pharma index fell nearly 2% on July 22, 2026, with major companies like Lupin, Aurobindo Pharma, and Cipla among the top losers.
Background
Indian pharmaceutical companies are major suppliers of generic drugs to the US, accounting for 40% of US generic drug imports. The US market represents about $10 billion in Indian pharma exports, with 90% of Indian drugmaker volumes in the US being generics.
Key facts
Trump announced phased tariffs: 100% from August 1, 2026, then 200% after two years.
The policy aims to incentivize generic drug manufacturers to set up production in the US.
Tariffs on patented and branded drugs remain unchanged.
India supplies 40% of generic drugs imported by the US.
Indian pharma exports to the US are valued at around $10 billion.
India has the largest number of USFDA-approved plants outside the US (about 670).
Manufacturing generic drugs in India costs 30-50% less than in the US.
Nifty Pharma fell nearly 2% on July 22, 2026, with all constituents trading lower.
Prelims pointers
- Nifty Pharma index
- USFDA (US Food and Drug Administration)
- Generic drugs vs branded drugs
- Tariff: a tax on imports
- Truth Social: Trump's social media platform
Mains angles
- Impact of US trade policies on Indian pharmaceutical exports
- India's dependence on the US market for generic drugs
- Strategies for Indian pharma companies to mitigate tariff risks
- Comparative cost advantage of Indian manufacturing vs US